Showing results (1-10 of 32) with videos related to
Sort By:
Pageof 4
Expert Review of Pharmacoeconomics & Outcomes Research|July 24, 2014
The economic burden of psoriasis: a systematic literature reviewSteven R Feldman, Chakkarin Burudpakdee, Smeet Gala, et al.Pharmacoeconomics|January 29, 2014
Treatment sequencing after failure of the first biologic in cost-effectiveness models of psoriasis: a systematic review of published models and clinical practice guidelinesJosephine Mauskopf, Miny Samuel, Doreen McBride, et al.Clinicoeconomics and Outcomes Research : CEOR|February 22, 2019
Sarilumab monotherapy compared with adalimumab monotherapy for the treatment of moderately to severely active rheumatoid arthritis: an analysis of incremental cost per effectively treated patientMarie Fournier, Chieh-I Chen, Andreas Kuznik, et al.Pharmacoeconomics|November 29, 2017
Budget Impact Analysis of PCSK9 Inhibitors for the Management of Adult Patients with Heterozygous Familial Hypercholesterolemia or Clinical Atherosclerotic Cardiovascular DiseaseUsha G Mallya, Susan H Boklage, Andrew Koren, et al.Journal of Developmental and Behavioral Pediatrics : JDBP|November 9, 2011
Medication utilization for targeted symptoms in children and adults with fragile X syndrome: US surveyDonald B Bailey, Melissa Raspa, Ellen Bishop, et al.Orphanet Journal of Rare Diseases|August 23, 2025
Psychometric evaluation of novel hyperphagia questionnaires in a real-world setting for patients with a rare MC4R pathway diseaseJeremy Pomeroy, Usha G Mallya, Min Yang, et al.The American Journal of Cardiology|March 18, 2018
Prescribing Patterns of Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors in Eligible Patients With Clinical Atherosclerotic Cardiovascular Disease or Heterozygous Familial HypercholesterolemiaDean G Karalis, Usha G Mallya, Ameen F Ghannam, et al.Advances in Therapy|February 22, 2022
Understanding the Patient Experience of Hunger and Improved Quality of Life with Setmelanotide Treatment in POMC and LEPR DeficienciesMartin Wabitsch, Sheri Fehnel, Usha G Mallya, et al.Obesity Science & Practice|August 7, 2023
Health state utilities associated with hyperphagia: Data for use in cost-utility modelsTimothy A Howell, Louis S Matza, Usha G Mallya, et al.Journal of Ophthalmic Inflammation and Infection|November 8, 2013
Healthcare costs and utilization for privately insured patients treated for non-infectious uveitis in the USADavid S Chu, Scott J Johnson, Usha G Mallya, et al.Pageof 4